News

Seven people in a group sitting together

New in vivo gene editing biotech blossoms from CRISPR pioneer Jennifer Doudna’s lab with $82M

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed with $82 million in funding and a dual-vector approach that the company hopes can enable permanent genome editing with a single dose. The funding total includes a $65 million series A that was led by Third Rock Ventures, with RA Capital Management, Yosemite and Sozo Ventures joining the financing bouquet.

Latest news121

A plate with two pieces of Umaro's seaweed bacon

Seaweed Bacon Is Coming to a Michelin-Starred Restaurant in S.F.

Plant-based bacon is challenging to pull off. But the version from Berkeley’s Umaro Foods is wooing investors and chefs. Read post
Little girl touching little boy's face

ResVita Bio receives Rare Pediatric Disease Designation for RVB-001 as a Treatment for Netherton Syndrome

"The physical and emotional challenges of chronic skin diseases are devastating to patients, particularly children" said Amin Zargar, Chief Executive Officer of ResVita Bio. "Newborns with Netherton Syndrome face a severe lifelong disease with few treatment options that offer limited efficacy. We are motivated by the prospect to deliver meaningful improvement in the lives of these patients, and this is a significant step towards the development RVB-001 as a treatment for Netherton Syndrome." Read post
Josh Yang of Glyphic Bio in their lab at Bakar Labs

How Berkeley Is Leaning in to the Biotech Boom

"Nowadays, they meet in person at the Bakar BioEnginuity Hub, the recently completed lab and office space that is emblematic of UC Berkeley’s efforts to support bioscience startups. It’s part of a web of startup activity on campus that’s so vast, the university created a website to help people navigate it." Read post